Five things for pharma marketers to know: Thursday, October 19, 2023

Five things for pharma marketers to know:

• BrainStorm Therapeutics said it is withdrawing its Biologics License Application and conducting a Phase IIIb clinical trial for its amyotrophic lateral sclerosis treatment NurOwn.

• Eli Lilly agreed to acquire another antibody-drug conjugate biotech, swooping in for France-based Mablink Bioscience, according to media reports.

• Intellia Therapeutics said the FDA cleared its Investigational New Drug application for its gene editing drug.

• SeaStar Medical shares rose sharply after the medical-device company won a third FDA breakthrough-device designation for its Selective Cytopheretic Device.

• Philanthropies with large stakes in weight-loss drugmakers Eli Lilly and Novo Nordisk have surged in value and are now among the biggest in the world.